The role of inositol in improving fertility in patients with PCOS
Authors:
- Kamila TurekKTKamila Turek
- Anna GregułaAGAnna Greguła
- Karol StachyrakKSKarol Stachyrak
- Dawid MikaDMDawid Mika
- Aleksandra KłosAKAleksandra Kłos
- Bartosz MazurBMBartosz Mazur
- Maciej LambachMLMaciej Lambach
- Mateusz PawlickiMPMateusz Pawlicki
- Aleksandra MazurekAMAleksandra Mazurek
- Wiktoria WilanowskaWWWiktoria Wilanowska
Open Access
- 7 February 2024
- journal article
- research article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 57, 126-139
Abstract
Introduction and purpose Polycystic ovary syndrome is a common reproductive disorder, accompanied primarily by hyperandrogenism and insulin resistance. Myo-inositol (MI) and D-chiro-inositol (DCI), have emerged as potential therapeutic agents due to their role as insulin sensitizers. This article examines the effects of inositol therapy on fertility in women with PCOS and its role in assisted reproductive technology (ART). Studies suggest that inositols alleviate irregular menstruation, reduce androgen levels and positively affect ovulation rates. MI supplementation has also shown positive effects during controlled ovarian hyperstimulation and IVF procedures, reducing the required FSH dose and cycle length. However, despite positive results on ovulation and menstrual regularity, the article indicates the need for further studies to establish inositol as standard ART therapy in patients with PCOS. Material and methods The following review was based on articles from the PubMed and Google Scholar databases. Key search terms included polycystic ovary syndrome; assisted reproductive treatment, insulin resistance, inositols, Myo-inositol, D-chiro-inositol. Conclusions Inositols are a promising therapeutic option for women with PCOS. They have been shown to have positive effects on improving insulin sensitivity and fertility. However, despite inositol's safety and easy availability, the ideal dose and timing of use, the appropriate MI/DCI ratio, as well as the potential side effects of excess DCI and the problem of inositol resistance, require further comprehensive studies.Keywords
This publication has 19 references indexed in Scilit:
- Myo-inositol in assisted reproductive technology from bench to bedsideTrends in Endocrinology & Metabolism, 2023
- Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART)Trends in Endocrinology & Metabolism, 2020
- Inositols in Polycystic Ovary Syndrome: An Overview on the AdvancesTrends in Endocrinology & Metabolism, 2020
- Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyondExpert Opinion on Drug Metabolism & Toxicology, 2020
- Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based ApproachTrends in Endocrinology & Metabolism, 2018
- Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta‐analysis of randomised trialsBJOG: An International Journal of Obstetrics & Gynaecology, 2017
- The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidanceHuman Reproduction Update, 2016
- D-chiro-inositol glycan stimulates insulin secretion in pancreatic β cellsMolecular and Cellular Endocrinology, 2014
- Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndromeGynecological Endocrinology, 2009
- Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte qualityHuman Reproduction, 2002